SG Americas Securities LLC Sells 117,571 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

SG Americas Securities LLC trimmed its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 74.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,350 shares of the biotechnology company’s stock after selling 117,571 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $311,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the last quarter. Quantinno Capital Management LP bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth approximately $82,000. SkyView Investment Advisors LLC increased its stake in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 3,000 shares during the last quarter. nVerses Capital LLC raised its holdings in shares of BioCryst Pharmaceuticals by 52.0% during the 3rd quarter. nVerses Capital LLC now owns 15,500 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 5,300 shares in the last quarter. Finally, Captrust Financial Advisors boosted its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,644 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BCRX. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Royal Bank of Canada restated an “outperform” rating and set a $10.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Evercore ISI lifted their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $15.50.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.09 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The firm has a 50-day simple moving average of $7.65 and a two-hundred day simple moving average of $7.70. The company has a market cap of $1.68 billion, a P/E ratio of -13.26 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.19) EPS. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 EPS for the current year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.